Bridgeway Capital Management’s aTyr Pharma ATYR Stock Holding History

Bridgeway Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,336	Closed	-$83K	–	1473
2018 Q3	$83K	Hold	7,336	–	–	﹤0.01%	1390
2018 Q2	$93K	Hold	7,336	–	–	﹤0.01%	1366
2018 Q1	$272K	Hold	7,336	–	–	﹤0.01%	1225
2017 Q4	$359K	Hold	7,336	–	–	﹤0.01%	1174
2017 Q3	$519K	Hold	7,336	–	–	0.01%	1081
2017 Q2	$354K	Hold	7,336	–	–	﹤0.01%	1177
2017 Q1	$359K	Hold	7,336	–	–	﹤0.01%	1162
2016 Q4	$221K	Hold	7,336	–	–	﹤0.01%	1297
2016 Q3	$327K	Buy	7,336 +3,929	+115%	+$170K	﹤0.01%	1220
2016 Q2	$133K	Buy	+3,407	New	+$158K	﹤0.01%	1361

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GHCM

Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

MCIM

Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bridgeway Capital Management's ATYR Position: Q4 2018 in Review

Bridgeway Capital Management sold out of aTyr Pharma (ATYR) in Q4 2018, closing a stake of 7,336 shares — an estimated $83K sold.

Bridgeway Capital Management first reported a position in ATYR in Q2 2016 and held it in 10 quarters. The position peaked at $519K in Q3 2017. 29 funds tracked by Wall St. Rank hold ATYR as of Q4 2018.

Bridgeway Capital Management reported no remaining aTyr Pharma position as of Q4 2018 after selling out during the quarter.
Bridgeway Capital Management sold 7,336 aTyr Pharma shares in Q4 2018, an estimated $83K.
Bridgeway Capital Management first reported a position in aTyr Pharma in Q2 2016 and held it in 10 quarters.
Bridgeway Capital Management's aTyr Pharma position peaked at $519K in Q3 2017.
29 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2018.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.